Industry News

• Global Blood Therapeutics announces proposed public offering of common stock  Global Blood Therapeutics announced an agreement to sell approximately $200.0 million in shares of its common stock in a registered underwritten public offering. GBT has granted underwriter a 30-day option to purchase up to approximately $30.0 million in shares of its common stock.
  June 25, 2019  
• Amarantus enters into LOI with Alchemists Kitchen for commercialization of hemp  Amarantus Bioscience announced a Letter of Intent with The Alchemist’s Kitchen to establish a joint venture for commercialization of hemp based herbal smokable products ‘Herbal Smokes’ in addition to conducting research for cannabinoid derived addiction treatment.
  June 25, 2019  
• Mirati Therapeutics announces pricing of public offering of common stock  Mirati Therapeutics announced pricing of an underwritten public offering of 2,100,000 shares of its common stock at a price to the public of $97.00 per share. Mirati granted underwriters a 30-day option to purchase up to an additional 315,000 shares of common stock.
  June 25, 2019  
• Halozyme announces CRADA with NIAID for ENHANZE® drug delivery technology  Halozyme announced a CRADA with the National Institute of Allergy and Infectious Diseases' Vaccine Research Center enabling the VRC's use of Halozyme's ENHANZE® drug delivery technology to develop subcutaneous formulations of bnAbs against HIV for HIV treatment.
  June 25, 2019  
• ArQule announces pricing of $90 million public offering of common stock  ArQule announced the pricing of an underwritten public offering of 9,250,000 shares of its common stock at a price to the public of $9.75 per share. ArQule granted underwriters a 30-day option to purchase up to an additional 1,387,500 shares of its common stock.
  June 25, 2019  
• AbbVie to acquire Allergan for $63 billion  AbbVie and Allergan announced an agreement under which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of AbbVie's common stock of $78.45 on June 24, 2019.
  June 25, 2019  
• Almirall exercises option with Dermira to license rights to lebrikizumab in Europe  Almirall and Dermira announced that Almirall has exercised its option to license rights to develop and commercialize lebrikizumab for treatment of atopic dermatitis and certain other indications in Europe. Almirall will pay Dermira $50 million and Dermira will be eligible to milestones.
  June 25, 2019  
• Gilead and Carna Bio announce R&D collaboration to develop immuno-oncology therapies  Gilead Sciences and Carna Biosciences announced the companies have entered into a research and development collaboration to develop and commercialize small molecule compounds in immuno-oncology and to access Carna’s proprietary lipid kinase drug discovery platform.
  June 24, 2019  
• Mirati Therapeutics announces proposed public offering of common stock  Mirati Therapeutics announced it has commenced an underwritten public offering of shares of its common stock. Mirati expects to grant the underwriters of the offering a 30-day option to purchase additional shares of its common stock at the public offering price.
  June 24, 2019  
• Conatus to explore strategic alternatives and implement restructuring plan  Conatus announced it has engaged Oppenheimer & Co. as its financial advisor to assist in the exploration and evaluation of strategic alternatives to enhance shareholder value. Conatus is implementing a restructuring plan that includes reducing staff by 40% and suspending development of CTS-2090.
  June 24, 2019  

   (next 10 articles)